Drug Eluting Stent Market Growth Predicted

The global drug eluting stent (DES) market size is expected to reach USD 13.65 billion by 2030, advancing at a CAGR of 8.4%. So says a new report from ResearchAndMarkets.com.

The new report is entitled “Drug Eluting Stent Market Size, Share & Trends Analysis Report By Coating Type (Polymer-based Coatings (Non-biodegradable, Biodegradable)), Polymer-free Coatings, By Application, By Region, And Segment Forecasts, 2023 – 2030”.

We’ve covered drug eluting stents extensively on our pages. To find out more, click here.

Drug Eluting Stent Trends

The report covers the factors that are expected to drive the demand for drug eluting stents over the forecast period. These include an aging population and the increasing prevalence of risk factors such as cardiovascular diseases (CVDs), complex lesions, diabetes, obesity, and others.

Additionally, ongoing technological advancements in stent design, including improvements in coatings and drug delivery mechanisms, are enhancing the safety and efficacy of these devices. This, says the report, will make them more appealing to patients and healthcare professionals.

The increasing prevalence of cardiovascular diseases globally has fueled market demand. Indeed the World Health Federation report in 2022 says over half a billion people globally continue to be affected. Moreover CVD contributed to approximately 20.5 million deaths in 2021, accounting for nearly a third of all deaths globally.

Conditions like coronary artery disease and peripheral artery disease are becoming increasingly common. This in turn has resulted in a surge in demand for effective treatment options such as DES. Moreover these stents, equipped with drug-coated surfaces, offer patients a minimally invasive solution. The drug element effectively prevents restenosis and leads to improved patient outcomes.

The market for drug eluting stents was significantly impacted by the COVID-19 pandemic. Manufacturers saw significant disruption to their supply chains. Since the focus of all major manufacturers was to fight the COVID-19 battle, the revenues of other segments were highly impacted. All notable competitors in the market for coronary stents saw interventional cardiology revenues decline in 2020.

Drug Eluting Stent Market Report Highlights

Based on coating, the polymer-based coating segment held the dominant revenue share of 82.9% in 2022. This can be attributed to its extensive usage in stent development, proven efficacy in drug delivery, and versatility in accommodating various therapeutic agents. Indeed this has made it a preferred choice for manufacturers and healthcare professionals alike. Additionally, continuous advancements in polymer-based coating technology have further solidified its leading position in the market

Based on application, the market for drug eluting stents has been categorized into coronary artery disease and peripheral artery disease. Of these, the former accounted for 85.9% of the revenue share in 2022. The growth can be attributed to the high prevalence of coronary artery disease globally. As a result there has been a substantial demand for effective treatment options such as drug eluting stents

The North American region held the largest revenue share of 43.08% in 2022. Indeed it is expected to dominate the market through the forecast period. This results from North America’s well-developed and advanced healthcare infrastructure, including hospitals. Additionally, the increasing prevalence of cardiovascular diseases in the region has driven the demand for effective treatment options such as drug eluting stents

Competitive Landscape

The report details all the major players in this market. These include Abbott, Boston Scientific, Terumo, Medtronic, Biosensors, Cook, B.Braun, Biotronik and Lepu Medical Technology.

For more information about the report, click here.

Source: Businesswire

Share your thoughts

Your email address will not be published. Required fields are marked *